Retatrutide Research for Type 2 Diabetes
An evidence-based overview of research examining Retatrutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 trials demonstrated glycemic improvement with HbA1c reductions of up to 2.02% at the 12mg dose (36 weeks), compared to essentially no change with placebo and 16.9% mean body-weight reduction in the 12 mg arm at 36 weeks. The first phase 3 confirmation, TRANSCEND-T2D-1 (n=537, 40 weeks), was published in June 2026: on the treatment-regimen estimand, HbA1c fell 1.69%, 1.86% and 1.94% at 4, 9 and 12 mg against 0.81% on placebo, and bodyweight fell 11.5%, 13.9% and 15.3% against 2.6%.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.